Mesa Laboratories, Inc. will release Q1 FY 2026 financial results on August 5, 2025, at 8:00 A.M. Eastern time.
Quiver AI Summary
Mesa Laboratories, Inc. will announce its financial results for the first quarter of fiscal year 2026 on August 5, 2025, at 8:00 A.M. Eastern time. The company is recognized as a leading provider of life science tools and quality control solutions for the pharmaceutical, healthcare, and medical device sectors. Mesa's mission is to assist clients in maintaining product integrity, enhancing safety for patients and workers, and improving overall quality of life. For further inquiries, interested parties can contact President and CEO Gary Owens or CFO John Sakys at the company's office. More information is available on their website.
Potential Positives
- Mesa Laboratories, Inc. will announce financial results for the first quarter of fiscal year 2026, indicating ongoing operational updates and transparency with stakeholders.
- The company is positioned as a global leader in the life sciences and quality control solutions sectors, suggesting a strong market presence and potential for growth.
- Products and services offered by Mesa are focused on ensuring product integrity and safety, which aligns with increasing regulatory standards in the pharmaceutical and healthcare industries, potentially enhancing business opportunities.
Potential Negatives
- Press release does not provide any specific financial data or insights, which may lead to uncertainty among investors and stakeholders regarding the company's performance.
- By announcing the financial results release date without any preliminary insights, it could indicate a lack of transparency or an attempt to manage expectations regarding potential outcomes.
- Failure to deliver earlier updates on the financial performance may reflect negatively on the company's communication strategy and responsiveness to market expectations.
FAQ
When will Mesa Laboratories release its Q1 fiscal 2026 financial results?
Mesa Laboratories will issue its Q1 financial results on August 5, 2025, at 8:00 A.M. Eastern time.
Who can I contact for more information about Mesa Laboratories?
You can contact Gary Owens, President and CEO, or John Sakys, CFO, at +1-303-987-8000.
What does Mesa Laboratories specialize in?
Mesa Laboratories specializes in life science tools and quality control solutions for the pharmaceutical and healthcare industries.
How can I learn more about Mesa Laboratories?
For more information about Mesa Laboratories, please visit their official website at www.mesalabs.com.
What industries does Mesa Laboratories serve?
Mesa Laboratories serves the pharmaceutical, healthcare, and medical device industries with its products and services.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MLAB Insider Trading Activity
$MLAB insiders have traded $MLAB stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $MLAB stock by insiders over the last 6 months:
- GARY M OWENS (President and CEO) has made 0 purchases and 2 sales selling 22,939 shares for an estimated $2,790,421.
- JOHN SAKYS (CFO) sold 642 shares for an estimated $62,349
- BRIAN DAVID ARCHBOLD (SVP Operations) sold 472 shares for an estimated $45,839
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MLAB Hedge Fund Activity
We have seen 68 institutional investors add shares of $MLAB stock to their portfolio, and 70 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SELECT EQUITY GROUP, L.P. added 60,186 shares (+439.0%) to their portfolio in Q1 2025, for an estimated $7,141,670
- KENNEDY CAPITAL MANAGEMENT LLC added 38,665 shares (+51.8%) to their portfolio in Q1 2025, for an estimated $4,587,988
- JANE STREET GROUP, LLC removed 27,380 shares (-79.6%) from their portfolio in Q1 2025, for an estimated $3,248,910
- CRAWFORD INVESTMENT COUNSEL INC added 26,200 shares (+inf%) to their portfolio in Q1 2025, for an estimated $3,108,892
- MORGAN STANLEY removed 24,236 shares (-10.1%) from their portfolio in Q1 2025, for an estimated $2,875,843
- RUSSELL INVESTMENTS GROUP, LTD. added 18,986 shares (+27.9%) to their portfolio in Q1 2025, for an estimated $2,252,878
- BLACKROCK, INC. removed 16,748 shares (-2.0%) from their portfolio in Q1 2025, for an estimated $1,987,317
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
LAKEWOOD, Colo., July 02, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the first quarter of fiscal year 2026 at approximately 8:00 A.M. Eastern time on Tuesday, August 5, 2025.
About Mesa Laboratories, Inc.
Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world.
CONTACT: Gary Owens, President and CEO, or John Sakys, CFO, both of Mesa Laboratories, Inc., +1-303-987-8000
For more information about the Mesa, please visit our website at www.mesalabs.com .
